Gleevec

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2020-05-01T09:56:32-04:00December 13th, 2019|Drug Treatment, Gleevec, LRG Science, News|

Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By |2019-11-26T11:49:16-05:00September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.

By |2019-09-23T11:28:24-04:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-04:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Study Indicates Use Of Adjuvant Imatinib Therapy For GIST Increasing

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]

By |2018-09-11T09:21:47-04:00April 7th, 2015|Drug Treatment, Gleevec, News, Survival Strategies|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By |2018-07-06T13:59:34-04:00January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Plasma Level Testing for Imatinib Now Available

Saladax Biomedical, a CLIA certified laboratory based in Bethlehem, Pennsylvania, is now providing plasma level testing for imatinib.(Gleevec). Testing is currently free of charge through January 31, 2015, as it is not covered by [...]

By |2019-04-08T08:46:39-04:00December 15th, 2014|Drug Treatment, Gleevec, News, Patient Support, Plasma Level Testing|